🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management Eur Urol Focus Sarah P. Psutka MD MS Philippe spiess Global Society of Rare GU Tumors eu-focus.europeanurology.com/article/S2405-…

#Orion study explores new paclitaxel-hyaluronic acid conjugate for BCG-unresponsive #BladderCancer. Sunil Patel MD and Sam S. Chang MD, MBA discuss a novel agent targeting CD44, overexpressed in bladder cancer cells and showing promising results > bit.ly/46WWGge

Thank you so much to IVUmed and South Central Section of the AUA for this unforgettable experience! I learned so much from the team of amazing Ghanaian doctors we worked with as well as the A-team, Drs. Poch, Sunil Patel MD, Kyle M Rose, and Josh Linscott.

Team lead by Drs. Michael Poch of Moffitt Urologic Oncology Fellowship and Sunil Patel MD of The Johns Hopkins Brady Urological Institute. Incredible job and leadership as always through great times and some obstacles

We brought a resectoscope to teach TURPs and TURBTs, huge thank you to OchsnerUrology Ochsner Health for supporting this endeavor with equipment and dedication to service and education

Work by Tony Su @bradyuro uses Markov modeling to ask the question we all wonder: does my bladder cancer patient really need 4 cystos a year? bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

BCG unresponsive trials should allow patients who are ineligible for BCG and recur after first-line Gem/Doce These patients need therapies too and will become a more common scenario over time! Bladder Cancer Advocacy Network

Congratulations to Claire de la Calle , MD, on receiving the Prostate Cancer Foundation Young Investigator Award! We asked Dr. de la Calle what this experience has meant to her, and she shared: "I am very excited about this project and honored to have received the PCF YIA. I have a

Looking forward to seeing everyone in Dallas for Society of Urologic Oncology meeting! Applicants who are interested in our excellent SUO fellowship, please reach out to me or Max Kates Arvin K. George, MD @cpavmd nirm Mohamad Allaf to learn more about the incredible experience at The Johns Hopkins Brady Urological Institute

It is normal for one testicle to be slightly larger than the other. Learn more about testicular cancer at TESTESCANCER.ORG #testicularcancer #testescancer #menshealthawareness #testicularcancerawareness #menshealth #earlydetection #malecancer #cancer #urology

Happy to talk to Any SUO fellowship applicants interested in learning more about our program at SUO.

Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors | JU auajournals.org/eprint/6NWNDSJ… w editorial reply auajournals.org/eprint/GIMJZZP… Muhannad Alsyouf Testicular Cancer Testicular Cancer Society Rob Hamilton Phillip Pierorazio DrBagrodia

Video in @UroToday with @maxkates, @urocancermd and @shpatelmd1: Gemcitabine and Docetaxel Combination Offers Promising Alternative to BCG in Bladder Cancer Treatment. Click here to watch: urotoday.com/video-lectures… here to watch the video:

🚨 Promising alternative to BCG for #NMIBC! Drs. Sunil Patel MD & Max Kates The Johns Hopkins Brady Urological Institute sit down with Sam S. Chang MD, MBA Vanderbilt Urology to discuss phase II trial results: 100% complete response at 3 months & 92% at 12 months with gemcitabine + docetaxel. Key takeaways: combination

Occupational and environmental factors linked to #BladderCancer in high-risk groups. Sunil Patel MD The Johns Hopkins Brady Urological Institute and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center joins in this discussion exploring the impact of exposure to burn pits among military veterans and environmental hazards faced by

🚨 Promising alternative to BCG for #NMIBC! Drs. Sunil Patel MD & Max Kates The Johns Hopkins Brady Urological Institute sit down with Sam S. Chang MD, MBA Vanderbilt Urology to discuss phase II trial results: 100% complete response at 3 months & 92% at 12 months with gemcitabine + docetaxel. Key takeaways: combination

TURBT is underrated and underappreciated by everyone except our patients. Michael E. Rezaee, MD, MPH called 150 of our patients before and 1,2,8,24 hrs,1 week after TURBT. Paper forthcoming. Results show us TURBT is a surgery like any other, with room for improvement and refinement

Just in time for AUA - A high-quality succinct review on contemporary intravesical therapy on NMIBC by the great Saum Ghodoussipour & all ⭐️ colleagues in European Urology Beautiful figures too! A valuable resource for patients & urologists Bladder Cancer Advocacy Network YUO pubmed.ncbi.nlm.nih.gov/40253283/

Ecstatic to have matched at Johns Hopkins The Johns Hopkins Brady Urological Institute for Society of Urologic Oncology fellowship! Thankful for everyone who has supported me along this journey, especially my mentors here at University of Kentucky Urology Residency Program! And yes… I decided to yolo and open my match results with my co-residents 😂🥰

We’re proud to congratulate and welcome Joon Kyung Kim, MD 김준경 to the Brady and into our Society of Urologic Oncology fellowship!! Great things to come in 2026! Johns Hopkins Medicine